GlobeImmune Inc
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also inv… Read more
GlobeImmune Inc (GBIM) - Total Assets
Latest total assets as of March 2016: $9.77 Million USD
Based on the latest financial reports, GlobeImmune Inc (GBIM) holds total assets worth $9.77 Million USD as of March 2016.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GlobeImmune Inc - Total Assets Trend (2010–2015)
This chart illustrates how GlobeImmune Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
GlobeImmune Inc - Asset Composition Analysis
Current Asset Composition (December 2015)
GlobeImmune Inc's total assets of $9.77 Million consist of 96.4% current assets and 3.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $209.72K | 1.8% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2015)
This chart illustrates how GlobeImmune Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GlobeImmune Inc's current assets represent 96.4% of total assets in 2015, an increase from 87.4% in 2010.
- Cash Position: Cash and equivalents constituted 86.1% of total assets in 2015, up from 85.7% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is property, plant & equipment at 1.8% of total assets.
GlobeImmune Inc Competitors by Total Assets
Key competitors of GlobeImmune Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
GlobeImmune Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - GlobeImmune Inc generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - GlobeImmune Inc is currently not profitable relative to its asset base.
GlobeImmune Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.28 | 3.27 | 0.93 |
| Quick Ratio | 2.28 | 3.27 | 0.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.30 Million | $ 10.38 Million | $ -838.93K |
GlobeImmune Inc - Advanced Valuation Insights
This section examines the relationship between GlobeImmune Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -37.4% |
| Total Assets | $11.51 Million |
| Market Capitalization | $575.00 USD |
Valuation Analysis
Below Book Valuation: The market values GlobeImmune Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: GlobeImmune Inc's assets decreased by 37.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GlobeImmune Inc (2010–2015)
The table below shows the annual total assets of GlobeImmune Inc from 2010 to 2015.
| Year | Total Assets | Change |
|---|---|---|
| 2015-12-31 | $11.51 Million | -37.36% |
| 2014-12-31 | $18.37 Million | +147.62% |
| 2013-12-31 | $7.42 Million | +74.90% |
| 2012-12-31 | $4.24 Million | -76.10% |
| 2011-12-31 | $17.75 Million | -25.04% |
| 2010-12-31 | $23.67 Million | -- |